Faculty Opinions recommendation of Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage.

Author(s):  
Chandra Kumar
Nature ◽  
2002 ◽  
Vol 419 (6908) ◽  
pp. 729-734 ◽  
Author(s):  
Joan Seoane ◽  
Hong-Van Le ◽  
Joan Massagué

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Rebecca A. Dagg ◽  
Gijs Zonderland ◽  
Emilia Puig Lombardi ◽  
Giacomo G. Rossetti ◽  
Florian J. Groelly ◽  
...  

AbstractBRCA1 or BRCA2 germline mutations predispose to breast, ovarian and other cancers. High-throughput sequencing of tumour genomes revealed that oncogene amplification and BRCA1/2 mutations are mutually exclusive in cancer, however the molecular mechanism underlying this incompatibility remains unknown. Here, we report that activation of β-catenin, an oncogene of the WNT signalling pathway, inhibits proliferation of BRCA1/2-deficient cells. RNA-seq analyses revealed β-catenin-induced discrete transcriptome alterations in BRCA2-deficient cells, including suppression of CDKN1A gene encoding the CDK inhibitor p21. This accelerates G1/S transition, triggering illegitimate origin firing and DNA damage. In addition, β-catenin activation accelerates replication fork progression in BRCA2-deficient cells, which is critically dependent on p21 downregulation. Importantly, we find that upregulated p21 expression is essential for the survival of BRCA2-deficient cells and tumours. Thus, our work demonstrates that β-catenin toxicity in cancer cells with compromised BRCA1/2 function is driven by transcriptional alterations that cause aberrant replication and inflict DNA damage.


2021 ◽  
Vol 7 (3) ◽  
pp. eabe3882
Author(s):  
Jenny F. Nathans ◽  
James A. Cornwell ◽  
Marwa M. Afifi ◽  
Debasish Paul ◽  
Steven D. Cappell

The G1-S checkpoint is thought to prevent cells with damaged DNA from entering S phase and replicating their DNA and efficiently arrests cells at the G1-S transition. Here, using time-lapse imaging and single-cell tracking, we instead find that DNA damage leads to highly variable and divergent fate outcomes. Contrary to the textbook model that cells arrest at the G1-S transition, cells triggering the DNA damage checkpoint in G1 phase route back to quiescence, and this cellular rerouting can be initiated at any point in G1 phase. Furthermore, we find that most of the cells receiving damage in G1 phase actually fail to arrest and proceed through the G1-S transition due to persistent cyclin-dependent kinase (CDK) activity in the interval between DNA damage and induction of the CDK inhibitor p21. These observations necessitate a revised model of DNA damage response in G1 phase and indicate that cells have a G1 checkpoint.


2002 ◽  
Vol 16 (3) ◽  
pp. 420-422 ◽  
Author(s):  
Troy R. Shirangi ◽  
Alex Zaika ◽  
Ute M. Moll

2010 ◽  
Author(s):  
David Reisman ◽  
Paula Takahashi ◽  
Amanda Polson
Keyword(s):  
S Phase ◽  

2012 ◽  
Vol 45 (6) ◽  
pp. 801-813 ◽  
Author(s):  
Svetlana V. Khoronenkova ◽  
Irina I. Dianova ◽  
Nicola Ternette ◽  
Benedikt M. Kessler ◽  
Jason L. Parsons ◽  
...  
Keyword(s):  

2006 ◽  
Vol 19 (4) ◽  
pp. 504-513 ◽  
Author(s):  
Gian F Zannoni ◽  
Beatrice Faraglia ◽  
Elisabetta Tarquini ◽  
Andrea Camerini ◽  
Karen Vrijens ◽  
...  

2018 ◽  
Vol 115 (3) ◽  
pp. 561-566 ◽  
Author(s):  
Melin J. Khandekar ◽  
Alexander S. Banks ◽  
Dina Laznik-Bogoslavski ◽  
James P. White ◽  
Jang Hyun Choi ◽  
...  

The peroxisome-proliferator receptor-γ (PPARγ) is expressed in multiple cancer types. Recently, our group has shown that PPARγ is phosphorylated on serine 273 (S273), which selectively modulates the transcriptional program controlled by this protein. PPARγ ligands, including thiazolidinediones (TZDs), block S273 phosphorylation. This activity is chemically separable from the canonical activation of the receptor by agonist ligands and, importantly, these noncanonical agonist ligands do not cause some of the known side effects of TZDs. Here, we show that phosphorylation of S273 of PPARγ occurs in cancer cells on exposure to DNA damaging agents. Blocking this phosphorylation genetically or pharmacologically increases accumulation of DNA damage, resulting in apoptotic cell death. A genetic signature of PPARγ phosphorylation is associated with worse outcomes in response to chemotherapy in human patients. Noncanonical agonist ligands sensitize lung cancer xenografts and genetically induced lung tumors to carboplatin therapy. Moreover, inhibition of this phosphorylation results in deregulation of p53 signaling, and biochemical studies show that PPARγ physically interacts with p53 in a manner dependent on S273 phosphorylation. These data implicate a role for PPARγ in modifying the p53 response to cytotoxic therapy, which can be modulated for therapeutic gain using these compounds.


Oncogene ◽  
1997 ◽  
Vol 15 (12) ◽  
pp. 1395-1406 ◽  
Author(s):  
Wiebke Janson ◽  
Gerhard Brandner ◽  
Johanna Siegel
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document